Stockscreener 앱 받기
100.90
0.27%
0.27
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
MIRM5806400 Bond Profile — Key Metrics - TradingView
Citizens raises Mirum Pharmaceuticals price target to $146 - scanx.trade
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK) - The Globe and Mail
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
US FDA approves Regeneron's rare bone disorder drug - Reuters
Mirum Pharmaceuticals(MIRM.US) Officer Sells US$4 Million in Common Stock - Moomoo
Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals SVP, Global Controller Sold Shares Worth Over $4M - TradingView
Mirum Pharmaceuticals (MIRM) SVP exercises 40k options, sells shares - Stock Titan
Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale - Stock Titan
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Rice Hall James & Associates LLC Acquires New Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
TimesSquare Capital Management LLC Invests $43 Million in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript - AOL.com
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative? - simplywall.st
Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell - MarketBeat
Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next - Yahoo Finance
Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management - Stock Titan
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The National Law Review
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 6,001 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (MIRM) CFO sells 6,001 shares in Rule 10b5-1 trade - Stock Titan
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares - Investing.com
Mirum Pharmaceuticals (MIRM) CEO trades 20,000 shares after option exercise under 10b5-1 plan - Stock Titan
(MIRM) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
MIRM (MIRM) insider files to sell 6,001 shares after recent stock sales - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
What is HC Wainwright's Forecast for MIRM FY2026 Earnings? - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A 40% Potential Upside for Investors in Rare Disease Therapies - DirectorsTalk Interviews
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC) - The Globe and Mail
MIRM (MIRM) insider Christopher Peetz plans 20,000-share sale after option exercise - Stock Titan
Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Q3 EPS Estimate for Mirum Pharmaceuticals Raised by Analyst - MarketBeat
TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold" - MarketBeat
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $118 to $140 - Moomoo
MIRUM PHARMACEUTICALS, INC. : RAYMOND JAMES RAISES TARGET PRICE TO $183 FROM $165 - webull.com
The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock By Investing.com - Investing.com Nigeria
TD Cowen Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00 - MarketBeat
Mirum Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $138.21, Implies 31% Upside - TradingView
Mirum Pharmaceuticals Slides as FDA Feedback Clouds Volixibat Timeline - Quiver Quantitative
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings - MarketBeat
FMR LLC reveals 6.2% Mirum Pharmaceuticals (MIRM) ownership in Schedule 13G - Stock Titan
RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating - marketscreener.com
HC Wainwright Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00 - MarketBeat
Citizens Jmp Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $137.00 - MarketBeat
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $135 to $140 - Moomoo
MIRM SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Mirum Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
MIRUM PHARMACEUTICALS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $140 FROM $185 - Bitget
Mirum Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Mirum shares sink after Q2 2026 sales beat - Investing.com
0.86%
0.31%
자본화:
|
볼륨(24시간):